抗人黑色素瘤单克隆抗体在荷瘤裸鼠体内的分布及其定位显像

本文观察了~(131)I 标记的黑色素瘤 McAb HB8759在荷瘤裸鼠体内的生物学分布及放射免疫显像。静脉注射 ~(131)I—McAb48h 和72h 后肿瘤与非肿瘤在5种主要脏器比活性比值(T/NT)分别平均为6.6和9.6,~(131)I—McAb 注射24h 后在移植瘤中明显定位浓集,48～72h 是放射免疫显像的最佳时间。     

~(131)I标记抗人结肠癌单克隆抗体MC_3在荷瘤裸鼠体内分布及肿瘤放射免疫显像

抗人结肠癌单克隆抗体(McAb)MC_3用~(131)Ⅰ标记后在裸鼠人肠癌模型上进行肿瘤定位和放射免疫显像研究。结果显示:体外标记抗体特异性结合率为37.5%,裸鼠体内在48～120h的ECT照相可见在肿瘤部位均有放射性的特异性浓聚,其摄取量随时间延长逐渐增加,肿瘤显影清晰,显像的合适时间为96～120h。而给予非特异性的~(131)Ⅰ-NMIgG后,肿瘤部位未见放射性浓聚,而呈全身均匀性分布。120h肿瘤组织与肝脏及正常肠组织的比值分别为3.61和9.81,肿瘤定位指数为4.26。病理组织学检查显示注射~(131)Ⅰ-MC_3裸鼠肿瘤呈大片坏死,仅局部肿瘤边缘尚存少数完整的肿瘤组织。提示McAbMC_3用于肠癌的诊断和导向治疗可能有良好的前景。     

~(131)I标记抗人结肠癌单克隆抗体MC3在荷瘤裸鼠体内分布及肿瘤放射免疫显像

抗人结肠癌单克隆抗体(McAb)MC3用~(131)I标记后,在裸鼠人肠癌模型上进行肿瘤定位和放射免疫显像研究。结果显示:体外标记抗体特异性结合率为37.5％。裸鼠体内在48～120h的ECT照相可见在肿瘤部     

抗乳腺癌单克隆抗体放射免疫显像及治疗的实验研究

本实验用~(131)I标记HDI,用正常小鼠IgG(NMIgG)做对照,在荷人乳腺癌裸鼠模型上,进行组织分布、肿瘤定位显像和治疗的实验研究。结果表明,~(131)I-HDI对肿瘤有明显的特异性浓聚。注射后72、96h,     

抗人结肠癌单克隆抗体SC3A在荷瘤裸鼠体内的放射免疫定位研究

本文报道采用Iodogen法以~(131)I标记的抗人结肠癌McAbs SC3A,在荷人结肠癌裸鼠体内的生物学分布及放射免疫定位显像研究的结果。McAb SC3A腹水经protein ASepharose 4B纯化后,SDS-PAGE电泳鉴定纯度,分子量为160kD。标记结果标记率在85％以上,放化纯度在95％以上。用同法     

~(131)I标记抗胃癌单克隆抗体(MG_7)在荷人胃癌裸鼠体内的分布及显像研究

本文观察~(131)I标记的抗胃癌的MG_7-McAb及其片段在移植人胃癌或结肠癌裸鼠体内的生物学分布及放射免疫显象。MG_7抗体在结肠癌(无关肿瘤)移植片 中无明显定位分布,静脉注射4只鼠的六种主要脏器及体液的肿瘤与非肿瘤比活性比值(T/NT)平均为1.32。该抗体及其片段在胃癌移植片中有明显定位浓集,其中F(ah′)_2段的浓集量(T/NT=4.9)大于全抗体(T/NT=3.0)。注射标记McAb后48～72h作放射免疫显象可见肿瘤的阳性图象,胃癌移植片的显像比结肠癌密集、清晰,注射标记F(ah′)_2片段者,胃癌的清晰显像时间可提前至注射后24h。     

~(131)I标记抗胃癌单克隆抗体(MG_7)在荷人胃癌裸鼠体内的分布及显像研究

本文观察~(131)I标记的抗胃癌的MG_7-McAb及其片段在移植人胃癌或结肠癌裸鼠体内的生物学分布及放射免疫显像。MG_7抗体在结肠癌(无关肿瘤)移植片中无明显定位分布,静脉注射4只鼠的六种主要脏器及体液的肿瘤与非肿瘤比活性比值(T/NT)平均为1:32。该抗体及其片段在胃癌移植片中有明显定位浓集,其中F(ab’)_2段的浓集量(T/NT=4.9)大于全抗体(T/NT=3.0)。注射标记McAb后48～72h作放射免疫显像可见肿瘤的阳性图像,胃癌移植     

131I标记抗胶质瘤单抗SZ-39在脑瘤病人体内分布及显像作用

应用改良氯胺T法以~(131)I标记本研究室制备的抗人脑胶质瘤单克隆抗体SZ-39,经静脉注入9例脑肿瘤患者体内,注射量0.7～2.2mic/100～300μg protein,然后通过SPECT观察~(131)I-McAbSZ-39在体内分布及对肿瘤的显像效果,并在注入抗体后4～     

~(131)I-抗胃癌单克隆抗体369及其F(ab′)_2片段在人胃癌移植瘤裸鼠体分布的研究

抗胃癌单克隆抗体3G9(McAb3G9)系本所生化室制备,与管癌组织和细胞有较好的选择性结合,其亚类为IgG_1。 用~(131)I标记3G9及其F(ab′)_2进行体内生物学分布和显像研究,用~(125)I标记正常小鼠     

胃癌单克隆抗体1D1-2在荷瘤裸鼠体内的放射免疫显像

本文应用人胃癌组织及细胞株移植建立了裸大鼠和裸小鼠两种胄癌移植模型。用~(125)I和~(131)I标记抗人胃癌单克隆抗体1D1-2,体外试验表明碘化1D1-2具有特异性的结合活性。注入荷瘤裸鼠体内72h后,显示该抗体高度浓集于肿瘤组织,浓聚指数为4.5,而正常组织仅为1.3,T/NT比分别为2～12倍,与胃组织比为3.2倍、放射免疫显像显示出清晰的肿瘤图像。提示单克隆抗体1D1-2应用于肿瘤定位诊断及导向治疗的可能性。     

In vivo detection of human hepatoma secreting hepatitis B surface antigen in nude mice with radiolabeled monoclonal antibodies that recognize distinct epitopes

Hepatitis B surface antigen (HBsAg), produced by a human hepatoma which had been transplanted into athymic nude mice, was specifically detected in vivo by 131I-labeled monoclonal antibodies (McAb) directed against distinct epitopes of HBsAg (anti-HBs). Significantly higher levels of radioactivity were present in the hepatoma secreting HBsAg when compared to either a non-HBsAg producing epidermoid tumor or most other tissues obtained from nude mice treated with the 131I-labeled anti-Hbs McAb. A radiolabeled control McAb that did not recognize HBsAg failed to discriminate between either the HBsAg positive and negative tumors or other tissues from nude mice. These data demonstrate the in vivo immunological specificity of anti-HBs McAb for HBsAg associated with a hepatoma tumor.     

抗人肝癌单克隆抗体HL2的制备及鉴定

用肝癌细胞株QGY-7703、BEL-7402、SMMC-7721以贯序法免疫BALB/c小鼠,获得一株分泌肝癌单抗的杂交窟株HL_2,其染色体数目为97—105。单抗HL_2系IgG_2b亚类。吸收实验及阻断实验证明HL_2抗原与CEA、AFP、HBsAg、HBcAg及HBeAg无免疫同源性。ABC法和ELISA法说明单抗HL_2与四株肝癌细胞、六例肝癌组织均呈明确阳性反应,除与SGC-7901、H_(128)、K_(562)、Hela细胞株及部分胚胎肝脏,胚胎结肠有较弱性反应外,与肝癌旁组织、正常肝脏、其它肿瘤组织和细胞株、二种正常人细胞及其它胚胎组织无反应。显示了单抗HL_2的特异性较好、阳性率较高,是一个有应用前景的单抗。     

婴儿双歧杆菌黑色素瘤靶向性的探讨

目的：探讨婴儿双歧杆菌对黑色素瘤组织的靶向性。方法：用^3H—TdR标记婴儿双歧杆菌，进行放射性体内参入示踪分析；组织切片革兰氏染色，进行图像分析。结果；仅瘤组织内放射性强度随时间延长持续增强，且存在大量革兰氏染色阳性紫蓝色深柒区。结论：婴儿双歧杆菌对黑色素瘤具有一定靶向性。     

抗骨肉瘤单克隆抗体2G10与骨源性肿瘤组织的免疫组化反应研究

用本室建立的１株抗人骨肉瘤组织的杂交瘤细胞所分泌的单克隆抗体２Ｇ１０进行ＡＢＣ法染色，对骨肉瘤和２０种其它肿瘤组织，以及２０余种正常人体组织进行了免疫组织化学定位研究。发现除了对部分骨源性肿瘤，尤其骨肉瘤有阳性反应外，对其它肿瘤均显示阴性反应；与正常成人以及胎儿的相应组织无交叉反应。     

Mesenchymal Stem Cell-mediated delivery of the sodium iodide symporter supports radionuclide imaging and treatment of breast cancer

Mesenchymal Stem Cells (MSCs) migrate specifically to tumors in vivo, and coupled with their capacity to bypass immune surveillance, are attractive vehicles for tumor-targeted delivery of therapeutic agents. This study aimed to introduce MSC-mediated expression of the sodium iodide symporter (NIS) for imaging and therapy of breast cancer. Tumor bearing animals received an intravenous or intratumoral injection of NIS expressing MSCs (MSC-NIS), followed by (99m) Technetium pertechnetate imaging 3-14 days later using a BazookaSPECT γ-camera. Tissue was harvested for analysis of human NIS (hNIS) expression by relative quantitative-polymerase chain reaction. Therapy animals received an i.p. injection of (131) I or saline 14 days after injection of MSC-NIS, and tumor volume was monitored for 8 weeks. After injection of MSC-NIS, BazookaSPECT imaging revealed an image of animal intestines and chest area at day 3, along with a visible weak tumor image. By day 14, the tumor was visible with a significant reduction in radionuclide accumulation in nontarget tissue observed. hNIS gene expression was detected in the intestines, heart, lungs, and tumors at early time points but later depleted in nontarget tissues and persisted at the tumor site. Based on imaging/biodistribution data, animals received a therapeutic dose of (131) I 14 days after MSC-NIS injection. This resulted in a significant reduction in tumor growth (mean ± SEM, 236 ± 62 mm(3) vs. 665 ± 204 mm(3) in controls). The ability to track MSC migration and transgene expression noninvasively in real time before therapy is a major advantage to this strategy. This promising data supports the feasibility of this approach as a novel therapy for breast cancer.     

抗人肺癌单克隆抗体(3D3)的研制及其特性鉴定

本文用人肺腺癌组织免疫的BALB/c小鼠脾细胞与小鼠骨髓瘤Sp2/0细胞融合,获得1株单克隆抗体(McAb 3D3)。Ig类测定为IgG_1型。杂交瘤培养上清液和腹水的效价分别为1∶10~3～10~4和1∶10~6。采用间接免疫荧光法(IFA)观察到McAb3D3主要与肺腺癌细胞株A549和L342反应,与其它组织肿瘤细胞株没有反应。ABC免疫酶染色试验显示McAb3D3主要与肺腺癌组织反应,与正常肺组织没有反应。     

Identification of Cytosolic Antigens from GW-39 Adenocarcinoma Cells by Crossed Immunoelectrophoresis and Immunofluorescence

Rabbits were immunized with a cytosolic fraction prepared from human adenocarcinoma cells of the colon (GW-39). The antibodies obtained were analyzed using crossed Immunoelectrophoresis and were found to precipitate 23 distinct antigens in the cytosolic fraction from colon tumor cells. After pre-absorption with human serum and plasma as well as acetone powders prepared from 2 normal human tissues and 4 normal hamster tissues, 1 major immunodominant cytosol antigen (CA-3) and two less intense immunoprecipitin peaks (CA-1 and CA-5) remained detectable by the crossed immunoelectrophoretic method. The preabsorptions with normal tissues were sufficiently complete to remove anti-carcinoembryonic antigen antibodies and showed that antigens CA-1, CA-3 and CA-5 are immunologically distinct from carcinoembryonic antigen.

Indirect immunofluorescence localization studies with pre-absorbed anti-cytosol antibodies and FITC-conjugated second antibody showed that these antigens were expressed in the cytoplasm and at the cell surface in several human colon tumor cell lines, their subclones and in primary colon tumor specimens.     

抗人结肠癌相关抗原单克隆抗体的制备及初步研究

目的：制备抗人结肠癌相关抗原的单克隆抗体4D10，运用组织芯片技术研究其与人结肠癌组织反应的情况。方汪：用人结肠癌细胞株LOVO免疫小鼠，用间接细胞ELISA和免疫组化的方法筛选抗结肠癌相关抗原的单抗。结果：获得一株能够稳定分泌抗人结肠癌相关抗原的杂交瘤细胞株。4D10能够与不同分期的结肠癌组织切片反应，且与正常组织和其他癌组织几乎不反应。结论：4D10对结肠癌的病理分期及预后结果都具有一定的临床参考价值。     

分泌抗人角蛋白单抗杂交瘤细胞株的建立及其抗体的初步鉴定

角蛋白(Keratin)作为一组分子量为40,000～70,000的不溶于水的细胞结构蛋白,广泛存在于哺乳类动物的上皮细胞内。而各种非上皮细胞中该蛋白成份缺如,因而角蛋白被认为是上皮来源细胞的一种标志物,引起了细胞生物学及病理学工作者的兴趣,尤其在肿瘤病理诊断方面,如通过角蛋白特异性抗体对肿瘤细胞进行角蛋白的